Abdullah Mohammed Al-Majid
Overview
Explore the profile of Abdullah Mohammed Al-Majid including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
261
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Barakat A, El-Senduny F, Islam M, Al-Majid A, Elshaier Y, Mazyed E, et al.
Pharmaceutics
. 2025 Jan;
17(1).
PMID: 39861743
This in vivo study introduces a newly developed spirooxindole derivative that is deemed safe and effective as a potential targeted therapy for various cancers. Extensive in vivo investigations, including histopathology,...
2.
Islam M, Al-Jassas R, Al-Majid A, Haukka M, Nafie M, Abu-Serie M, et al.
RSC Med Chem
. 2024 Aug;
15(8):2937-2958.
PMID: 39149093
The unique structure of spirooxindoles and their ability to feature various pharmacophoric motifs render them privileged scaffolds for tailoring new multitarget anticancer agents. Herein, a stereoselective multicomponent reaction was utilized...
3.
Barakat A, Alshahrani S, Al-Majid A, Alamary A, Haukka M, Abu-Serie M, et al.
Front Pharmacol
. 2024 Apr;
15:1358089.
PMID: 38650632
This study discusses the synthesis and use of a new library of spirooxindole-benzimidazole compounds as inhibitors of the signal transducer and activator of p53, a protein involved in regulating cell...
4.
Nafie M, Al-Majid A, Ali M, Alayyaf A, Haukka M, Ashraf S, et al.
Front Chem
. 2024 Mar;
12:1364378.
PMID: 38487783
Cancer represents a global challenge, and the pursuit of developing new cancer treatments that are potent, safe, less prone to drug resistance, and associated with fewer side effects poses a...
5.
Barakat A, Alshahrani S, Al-Majid A, Alamary A, Haukka M, Abu-Serie M, et al.
Bioorg Chem
. 2023 Dec;
143:107012.
PMID: 38071087
No abstract available.
6.
Barakat A, Alshahrani S, Al-Majid A, Alamary A, Haukka M, Abu-Serie M, et al.
J Enzyme Inhib Med Chem
. 2023 Nov;
38(1):2281260.
PMID: 37994663
Despite the crucial role of CDK2 in tumorigenesis, few inhibitors reached clinical trials for managing lung cancer, the leading cause of cancer death. Herein, we report combinatorial stereoselective synthesis of...
7.
Alshahrani S, Al-Majid A, Alamary A, Ali M, Altowyan M, Rios-Gutierrez M, et al.
Molecules
. 2023 Oct;
28(19).
PMID: 37836817
A new series of spirooxindoles based on benzimidazole, triazole, and isatin moieties were synthesized via a [3+2] cycloaddition reaction protocol in one step. The single X-ray crystal structure of the...
8.
Islam M, Al-Majid A, Haukka M, Parveen Z, Ravaiz N, Wadood A, et al.
Chem Biol Drug Des
. 2023 Aug;
102(5):972-995.
PMID: 37563748
A novel spirooxindole-pyrrolidine clubbed thiochromene and pyrazole motifs were synthesized by [3+2] cycloaddition (32CA) reactions in one step process starting from the ethylene-based thiochromene and pyrazole scaffolds with the secondary...
9.
Al-Jassas R, Islam M, Al-Majid A, Nafie M, Haukka M, Rahman A, et al.
Arch Pharm (Weinheim)
. 2023 May;
356(8):e2300185.
PMID: 37253118
A series of 16 novel spirooxindole analogs 8a-p were designed and constructed via cost-effective single-step multicomponent [3+2] cycloaddition reaction of azomethine ylide (AY) generated in situ from substituted isatin (6a-d)...
10.
Islam M, Al-Majid A, Sholkamy E, Barakat A, Viale M, Menichini P, et al.
Sci Rep
. 2023 May;
13(1):7441.
PMID: 37156796
Recently, cancer research protocols have introduced clinical-stage spirooxindole-based MDM2 inhibitors. However, several studies reported tumor resistance to the treatment. This directed efforts to invest in designing various combinatorial libraries of...